<DOC>
	<DOC>NCT00975988</DOC>
	<brief_summary>Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients according to the prescribing information TYKERB® is a registered trademark of the GlaxoSmithKline group of companies.</brief_summary>
	<brief_title>Regulatory TYKERB® Tablets PMS</brief_title>
	<detailed_description>Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients according to the prescribing information TYKERB® tablets will be administered with capecitabine for HER2 overexpressing advanced or metastatic breast cancer treatment or with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 as described the prescribing information of TYKERB® tablets</detailed_description>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>All subjects must satisfy the following criteria at PMS entry according to MFDS PMS regulation: Subjects with indication in the locally approved prescribing information Subjects with no contraindication according to the prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>PMS (post-marketing surveillance)</keyword>
	<keyword>TYKERB® tablets</keyword>
</DOC>